LungLife AI

Lung Life Ai

Biotechnology, 2545 W Hillcrest Dr, Thousand Oaks, California, 91320, United States, 11-50 Employees

lunglifeai.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: +12*********

Who is LUNGLIFE AI

LungLife is a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence. The Company's diagnostic solutions are designed to make a significant impact ...

Read More

map
  • 2545 W Hillcrest Dr, Thousand Oaks, California, 91320, United States Headquarters: 2545 W Hillcrest Dr, Thousand Oaks, California, 91320, United States
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • Paul Pagano CEO:   Paul Pagano

industries-icon Industry: Biotechnology

SIC SIC Code: 8071

checked-icon Does something look wrong? Fix it. | View contact records from LUNGLIFE AI

LungLife AI Org Chart and Mapping

VP-Level
VP-Level

Lara Baden

VP Clinical Laboratory Operations

Employees

Brad McCoy

Clinical Study Manager

Katelyn Palladino

Executive Assistant to Ceo/Cfo

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding LungLife AI

Answer: LungLife AI's headquarters are located at 2545 W Hillcrest Dr, Thousand Oaks, California, 91320, United States

Answer: LungLife AI's phone number is +12*********

Answer: LungLife AI's official website is https://lunglifeai.com

Answer: LungLife AI's revenue is $5 Million to $10 Million

Answer: LungLife AI's SIC: 8071

Answer: LungLife AI has 11-50 employees

Answer: LungLife AI is in Biotechnology

Answer: LungLife AI contact info: Phone number: +12********* Website: https://lunglifeai.com

Answer: LungLife is a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence. The Company's diagnostic solutions are designed to make a significant impact in the early detection of lung cancer. The Company's technology is a combination of the recovery of rare cells and blood-based biomarkers shown to be altered in lung cancer. The Company employs machine learning to improve biomarker detection, and intends to build a deep, novel pool of lung cancer-related data for AI-enabled applications designed to improve its diagnostic solutions over time. The Company's core technologies are integrated in the LungLB test, which is intended to be used as a tool to provide physicians with additional information to help in the decision-making process for people with indeterminate lung nodules that may be lung cancer following a CT scan. There are estimated to be over 1.5 million individuals with indeterminate lung nodules diagnosed each year in the United States. The LungLB test may have additional utilities, the most significant of which is likely to be in monitoring individuals for recurrence following surgical removal of cancerous lung nodules. The Company has completed a 149 subject pilot study to evaluate the LungLB test, which showed a well-balanced performance and a Positive Predictive Value of 89 per cent. The Company is now gearing up to proceed to a larger, multi-centre validation study to garner regulatory and reimbursement support and facilitate commercialisation.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access